Prime Medicine, Inc.
PRME$746M
Small CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE214 employees
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Drugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PRME News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
PG-011Gel
Atopic Dermatitis
PM359
Chronic Granulomatous Disease
Pumecitinib Nasal Spray 0.3%
Seasonal Allergic Rhinitis
Bemarituzumab
Gastric Cancer
FPA008
Pigmented Villonodular Synovitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PG-011Gel | Phase 3 | Atopic Dermatitis | - | - |
PM359 | Phase 2 | Chronic Granulomatous Disease | - | - |
Pumecitinib Nasal Spray 0.3% | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Bemarituzumab | Phase 2 | Gastric Cancer | - | - |
FPA008 | Phase 2 | Pigmented Villonodular Synovitis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply